Urology 1997 Nov;50(5):809-811
MUSE therapy: preliminary clinical observations.
Werthman P, Rajfer J
Department of Urology, University of California at Los Angeles School of Medicine 90095-1738, USA.
OBJECTIVES: Intracavernosal injection of vasodilating agents has been a mainstay in the treatment of
erectile dysfunction. Recently, a transurethral delivery system (MUSE) for alprostadil (prostaglandin E1)
was introduced as an alternative form of pharmacotherapy. METHODS: One hundred consecutive
patients with erectile dysfunction were treated with MUSE in doses ranging from 125 to 1000
micrograms and their erections were observed in the clinical setting. All patients had previous
intracavernosal injections of combination pharmacotherapy (papavarine, Regitine, and/or
prostaglandin E1). RESULTS: Of these 100 patients that used MUSE, only 7% had well-sustained, rigid
erections while 30% had full erections but with partial rigidity. The remaining 63% of patients did not
achieve erections that they thought were adequate for penetration. Penile and/or perineal pain
occurred in 24% of patients, 3% had a syncopal episode, and 3% experienced urethral bleeding. One
patient had priapism that required drainage. Using intracavernosal injections, 49% had sustained rigid
erections, 40% had full erections with partial rigidity, and 11% did not have a response satisfactory for
penetration. CONCLUSIONS: These data suggest that intracavernosal injections appear to be more
effective than MUSE in achieving a rigid erection in men with erectile dysfunction.
Publication Types:
Clinical trial
PMID: 9372900, UI: 98040182 |
